The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

NVS FINANCIAL STATEMENTS

Novartis AG ADR — balance sheet, income statement and cash flow trends

NVSNovartis AG ADR

🇺🇸 USA · US · Healthcare · Drug Manufacturers - General

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
020 B40 B202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue56.1 B $Gross Profit42.2 B $ · 75%Operating Income17.1 B $ · 31%Pre-tax Income15.8 B $ · 28%Net Income13.5 B $ · 24%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue56.1 B $+5.3%
Gross Profit42.2 B $+4.8%
Operating Income17.1 B $+8.1%
EBITDA22.4 B $+2.4%
Net Income13.5 B $+5.2%

Peer Comparison· Drug Manufacturers - General

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
NVS5.3%75.3%40.0%24.1%
Industry median3.3%70.7%28.4%15.0%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
050 B100 B202120222023202420252026

Capital Structure

Q1 2026
Total Assets118.5 B
  • Equity38.5 B $33%
  • Current Liabilities31.4 B $27%
  • Long-term Liabilities48.2 B $41%

Key Figures

YoY change
Total Assets118.5 B $+18.6%
Total Liabilities79.6 B $+29.5%
Total Equity38.5 B $+0.4%
Cash & ST Investments7 B $-3.0%
Total Debt47 B $+50.3%
Net Debt40.1 B $+65.8%

Peer Comparison· Drug Manufacturers - General

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
NVS0.85122.0%1.7932.5%
Industry median1.2594.3%1.3528.4%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
010 B20 B202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
010 B20 B19.2 B $Operating-17 B $Investing-2.7 B $Financing-495.4 M $Net Change

Key Figures

YoY change
Operating Cash Flow19.2 B $+0.9%
Capital Expenditures2.8 B $-32.4%
Free Cash Flow16.4 B $+10.2%
Dividends Paid-8.6 B $-156.2%

Peer Comparison· Drug Manufacturers - General

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
NVS34.2%29.2%5.0%141.6%
Industry median23.7%18.5%5.3%137.9%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on NVS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.